# NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy

> **NIH NIH R44** · NANOVALENT PHARMACEUTICALS, INC. · 2020 · $892,769

## Abstract

This Phase II SBIR project seeks to demonstrate that novel, targetable nanoparticles
can delivery therapeutic substances to human tumor cells and reduce tumor burden in
cancer. The concept for these nanoparticles is based on the hybrid polymerized
liposome nanoparticle (HPLN) that displays functional antibodies that target tumor cell
surface markers. The therapeutic cargos are encapsulated cytotoxic drugs that comprise
the front line treatment for Ewing sarcoma. Upon recognition by the tumor cell, the
nanoparticle binds, gets taken into the cell (endocytosed) and the nanoparticle cargo is
released, ultimately allowing availability of the drug to kill the cancer cell. This project fits
well within the mission of the NCI, to develop new nanotechnology-based therapeutics.
Treatment-resistant metastases are the ultimate cause of death in most cancer patients.
Systemic therapy for metastases is generally ineffective. A reliable, low-toxic, highly
effective therapy is urgently needed to treat both relapse patients and treatment-resistant
metastases. The specific aims of this proposal are therefore to optimize the
HPLN particle, carry out efficient encapsulation of cancer drugs inside the targeted
HPLNs, demonstrate safety and efficacy in killing cancer cells in a humanized xenograft
mouse model of human Ewing sarcoma. The first aim is to determine the maximal
tolerated dose (MTD) in healthy animals and the PK-efficacy relationship in tumor-bearing
mice. NanoValent’s goal, at the conclusion of the Phase II is to have an
optimized formulation that can be GMP manufactured and subsequently gather the
necessary data for an IND submission to the FDA for approval of this novel therapy.

## Key facts

- **NIH application ID:** 9919322
- **Project number:** 5R44CA233128-03
- **Recipient organization:** NANOVALENT PHARMACEUTICALS, INC.
- **Principal Investigator:** JON Owen NAGY
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $892,769
- **Award type:** 5
- **Project period:** 2018-09-14 → 2021-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9919322

## Citation

> US National Institutes of Health, RePORTER application 9919322, NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy (5R44CA233128-03). Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/grant/nih/9919322. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*